161 related articles for article (PubMed ID: 27612977)
21. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.
Pectasides D; Farmakis D; Koumarianou A
Oncology; 2005; 68(1):64-70. PubMed ID: 15809522
[TBL] [Abstract][Full Text] [Related]
22. [PRIMARY CYTOREDUCTIVE SURGERY VERSUS NEOADJUVANT CHEMOTHERARY IN TREATMENT OF ADVANCED OVARIAN CANCER (STAGE III C-IV). OUR AND FOREIGN EXPERIENCE].
Ivanov S; Kovachev E; Kolev N; Bechev B; Kolev N
Akush Ginekol (Sofiia); 2016; 55 Suppl 1 Pt 1():16-9. PubMed ID: 27514164
[TBL] [Abstract][Full Text] [Related]
23. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
Bristow RE; Eisenhauer EL; Santillan A; Chi DS
Gynecol Oncol; 2007 Feb; 104(2):480-90. PubMed ID: 17166564
[TBL] [Abstract][Full Text] [Related]
24. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
van Meurs HS; Tajik P; Hof MH; Vergote I; Kenter GG; Mol BW; Buist MR; Bossuyt PM
Eur J Cancer; 2013 Oct; 49(15):3191-201. PubMed ID: 23850170
[TBL] [Abstract][Full Text] [Related]
25. Timing of debulking surgery in advanced ovarian cancer.
Vergote I; van Gorp T; Amant F; Leunen K; Neven P; Berteloot P
Int J Gynecol Cancer; 2008; 18 Suppl 1():11-9. PubMed ID: 18336393
[TBL] [Abstract][Full Text] [Related]
26. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients.
Inciura A; Simavicius A; Juozaityte E; Kurtinaitis J; Nadisauskiene R; Svedas E; Kajenas S
BMC Cancer; 2006 Jun; 6():153. PubMed ID: 16759398
[TBL] [Abstract][Full Text] [Related]
27. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
28. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
Liu EL; Mi RR
Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
[TBL] [Abstract][Full Text] [Related]
30. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future?
Schorge JO; Bradford LS; del Carmen MG
Clin Adv Hematol Oncol; 2011 Dec; 9(12):912-8. PubMed ID: 22252659
[TBL] [Abstract][Full Text] [Related]
31. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Salinaro JR; McQuillen K; Stemple M; Boccaccio R; Ehrisman J; Lorenzo AM; Havrilesky L; Secord AA; Galvan Turner V; Moore KN; Davidson B
Int J Gynecol Cancer; 2020 Apr; 30(4):491-497. PubMed ID: 32054646
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I; Tropé CG; Amant F; Kristensen GB; Ehlen T; Johnson N; Verheijen RH; van der Burg ME; Lacave AJ; Panici PB; Kenter GG; Casado A; Mendiola C; Coens C; Verleye L; Stuart GC; Pecorelli S; Reed NS; ;
N Engl J Med; 2010 Sep; 363(10):943-53. PubMed ID: 20818904
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
34. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer.
Melamed A; Rauh-Hain JA; Gockley AA; Nitecki R; Ramirez PT; Hershman DL; Keating N; Wright JD
JAMA Oncol; 2021 Dec; 7(12):1782-1790. PubMed ID: 34591081
[TBL] [Abstract][Full Text] [Related]
35. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
36. Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.
Lin JJ; Egorova N; Franco R; Prasad-Hayes M; Bickell NA
Obstet Gynecol; 2016 Jan; 127(1):81-89. PubMed ID: 26646132
[TBL] [Abstract][Full Text] [Related]
37. Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Schwartz L; Schrot-Sanyan S; Brigand C; Baldauf JJ; Wattiez A; Akladios C
Anticancer Res; 2015 Oct; 35(10):5503-9. PubMed ID: 26408716
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
39. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?
Schwartz PE
Oncology (Williston Park); 2008 Sep; 22(10):1118-25; discussion 1130, 1132, 1134. PubMed ID: 18935925
[TBL] [Abstract][Full Text] [Related]
40. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
